foscarnet has been researched along with Local Neoplasm Recurrence in 4 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ganciclovir (GCV) and foscarnet (FCN) are effective anti-cytomegalovirus (CMV) preemptive therapies; however, the impact of the 2 agents on various clinical outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) remains unclear." | 8.02 | Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. ( Iida, H; Ino, K; Kajiguchi, T; Kasahara, S; Kasai, M; Kohno, A; Kurahashi, S; Kusumoto, S; Miyao, K; Morishita, T; Murata, M; Nishida, T; Ozawa, Y; Sawa, M; Takami, A; Terakura, S, 2021) |
| "Ganciclovir (GCV) and foscarnet (FCN) are effective anti-cytomegalovirus (CMV) preemptive therapies; however, the impact of the 2 agents on various clinical outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) remains unclear." | 4.02 | Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. ( Iida, H; Ino, K; Kajiguchi, T; Kasahara, S; Kasai, M; Kohno, A; Kurahashi, S; Kusumoto, S; Miyao, K; Morishita, T; Murata, M; Nishida, T; Ozawa, Y; Sawa, M; Takami, A; Terakura, S, 2021) |
| "Foscarnet (90 mg/kg) was given every 12 h, day +11 to day +16." | 1.31 | Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation? ( Bornhäuser, M; Ehninger, G; Geissler, G; Kroschinsky, F; Naumann, R; Ordemann, R; Schwerdtfeger, R, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyao, K | 1 |
| Terakura, S | 1 |
| Ozawa, Y | 1 |
| Sawa, M | 1 |
| Kohno, A | 1 |
| Kasahara, S | 1 |
| Iida, H | 1 |
| Ino, K | 1 |
| Kusumoto, S | 1 |
| Kasai, M | 1 |
| Takami, A | 1 |
| Kurahashi, S | 1 |
| Kajiguchi, T | 1 |
| Morishita, T | 1 |
| Nishida, T | 1 |
| Murata, M | 1 |
| Toro, J | 1 |
| Rivera, JS | 1 |
| Moutran-Barroso, H | 1 |
| Valencia-Enciso, N | 1 |
| Inaba, H | 1 |
| Rabah, R | 1 |
| Meert, KL | 1 |
| BhamBhani, K | 1 |
| Ordemann, R | 1 |
| Naumann, R | 1 |
| Geissler, G | 1 |
| Kroschinsky, F | 1 |
| Bornhäuser, M | 1 |
| Schwerdtfeger, R | 1 |
| Ehninger, G | 1 |
4 other studies available for foscarnet and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy.
Topics: Antiviral Agents; Cytomegalovirus; Foscarnet; Ganciclovir; Humans; Neoplasm Recurrence, Local; Retro | 2021 |
Acute HSV and anti-NMDA encephalitis occurring as a neurosurgical complication.
Topics: Acyclovir; Adult; Antiviral Agents; Encephalitis, Herpes Simplex; Foscarnet; Humans; Male; Neoplasm | 2021 |
Herpes simplex virus pneumonia in a patient with ependymoma.
Topics: Acyclovir; Antiviral Agents; Brain Neoplasms; Child, Preschool; Drug Therapy, Combination; Ependymom | 2004 |
Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Hematopoietic Stem Cell Tran | 2000 |